Actos Bladder Cancer Lawsuit
Written by Faith Anderson on June 18, 2012
Actos and Bladder Cancer Side Effects
Although most lawsuits filed against Takeda involve individuals who developed bladder cancer after using Actos for long periods of time, Andrews claims that he was diagnosed with the disease in October 2011 after using the medication between April and July 2011. Actos (pioglitazone) was approved by the Food and Drug Administration in July 1999 as a treatment for type 2 diabetes, and it is a once-daily pill that functions by increasing the body’s sensitivity to insulin.
FDA Warnings for Actos Side Effect Risk
Over the past 18 months, serious concerns have been raised about the risk of bladder cancer associated with the diabetes drug Actos, as interim data released in September 2010 showed that long-term use of the diabetes drug was linked to an increased risk of bladder cancer. In June 2011, the FDA issued a drug safety communication alerting consumers that new information would be added to the Actos warning label, indicating that patients who use the diabetes drug for more than one year may have an increased risk of developing bladder cancer. In response to this risk, regulators in France removed Actos from the market, but the FDA has not yet indicated that an Actos recall will be issued in the United States.
Actos Lawsuits for Bladder Cancer Side Effects
According to Andrews, Takeda Pharmaceuticals concealed its knowledge that Actos can cause bladder cancer, and he claims that the medication was the direct and proximate cause of his disease. “Takeda Pharmaceuticals actually knew of the defective nature of their product…yet continued to design, manufacture, market, distribute and sell [Actos] so as to maximize sales and profits at the expense of the general public’s health and safety in conscious disregard of the foreseeable harm caused by this product,” Andrews says in the lawsuit. Andrews’ lawsuit joins a growing number of cases brought against the drug company in federal and state courts throughout the United States.